By Reuters Staff
BEIJING (Reuters) – China’s CanSino Biologics Inc. has recruited over 20,000 participants for late-stage human trials overseas for its coronavirus vaccine, a health official said on Monday.
The candidate, known as Ad5-nCoV or Convidecia, which CanSinoBIO is jointly developing with a research institute backed by the Chinese military, is among the five vaccines China has moved into Phase 3 clinical trials to test their efficacy.
“As for now, the number of recruited participants has exceeded 20,000 people, and the progress is relatively fast,” said Zheng Zhongwei, an official at China’s National Health Commission, told a press conference.
Phase 3 trials for CanSinoBIO’s candidate, which are planned to involve 40,000 participants in total, have begun enrolling participants in Pakistan, Russia, Mexico and Chile, the latest clinical trial registration data showed. https://bit.ly/3mHzt8R
Absolutely Maybe
We’re into the 12th month since sequencing of the genome of SARS-Cov-2, the virus that causes Covid-19. And we have 2 Covid vaccines across the line of convincing phase 3 trial results released, plus emergency use authorization or approval. How far are we now, and why did some sprint ahead while others fell behind? Let’s start with what we know from the handful of vaccines with at least some data released.
Main takeaways about Covid vaccines so far
There are important, often major, differences in the characteristics and effects of the vaccines.
2 vaccines have been convincingly shown to have high efficacy against getting sick with Covid-19 – BNT/Pfizer’s and NIH/Moderna’s.
Die schwierige Wiedergeburt des „Schwarzgesicht-Doktors Yi Fan german.cri.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from german.cri.cn Daily Mail and Mail on Sunday newspapers.
Zhang Chenlin / Xinhua News Agency/Getty Images
Originally published on December 16, 2020 11:22 am
China now reports few to none domestically transmitted COVID-19 cases only 12 cases were reported on Dec. 15.
But a flurry of recent cases has Chinese public health officials worried. They claim that the cases stemmed from workers who had contact with imported food and packages.
Beijing has now banned nearly 100 suppliers from 20 countries and at one point recommended travel restrictions in at least two cities where frozen food handlers contracted the coronavirus.
There s a problem with this theory. The cases directly contradict international health guidance, which says such transmission is highly unlikely. Emanuel Goldman, a microbiologist at Rutgers University s New Jersey Medical School, wrote in the Lancet this summer that the chance of transmission through inanimate surfaces is very small, adding that objects not in contact with an infected carrier for many hours